Found 2 hits Enz. Inhib. hit(s) with Target = 'IgG receptor FcRn large subunit p51' and Ligand = 'BDBM50270831' Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270831
((2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S...)Show SMILES CC(C)C[C@H](NC(=O)CN(C)C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:80.82,95.100,28.36,50.60,42.44,4.4,74.78,wD:61.64,17.25,46.48,99.103,(29.75,3.77,;29.75,2.23,;31.09,1.45,;28.41,1.45,;28.41,-.09,;27.08,-.86,;25.75,-.09,;25.75,1.45,;24.42,-.86,;23.08,-.1,;23.09,1.44,;21.75,-.87,;21.75,-2.41,;20.42,-.1,;19.08,-.87,;17.75,-.1,;17.75,1.44,;16.42,-.87,;16.42,-2.41,;17.75,-3.18,;19.08,-2.41,;20.41,-3.18,;20.42,-4.72,;19.09,-5.49,;17.75,-4.73,;15.09,-.1,;13.76,-.88,;13.76,-2.42,;12.42,-.11,;12.42,1.44,;13.76,2.2,;15.17,1.58,;16.19,2.73,;15.42,4.06,;13.91,3.73,;11.08,-.86,;9.74,-.09,;9.74,1.45,;8.41,-.87,;7.08,-.08,;5.75,-.87,;5.75,-2.41,;4.42,-.1,;3.08,-.87,;1.75,-.1,;1.75,1.45,;.42,-.87,;-.91,-.1,;-2.24,-.88,;-2.24,-2.42,;-3.58,-.11,;-3.58,1.44,;-2.24,2.2,;-.9,1.43,;.43,2.2,;.43,3.75,;-.92,4.51,;-2.24,3.73,;-4.92,-.86,;-6.26,-.1,;-6.26,1.44,;-7.59,-.88,;-8.94,-.08,;-7.59,-2.41,;-6.26,-3.18,;-6.26,-4.72,;-4.92,-5.49,;-4.92,-7.03,;-6.27,-7.77,;-3.6,-7.79,;.42,-2.41,;1.97,-2.41,;-1.12,-2.4,;.42,-3.95,;4.42,1.45,;3.09,2.21,;5.75,2.21,;29.74,-.86,;29.74,-2.4,;31.08,-.09,;32.41,-.86,;33.74,-.09,;33.74,1.45,;32.42,2.22,;32.41,3.75,;33.75,4.53,;33.75,6.07,;35.08,3.77,;35.09,2.23,;32.41,-2.4,;31.08,-3.17,;33.74,-3.17,;35.32,-2.64,;36.34,-3.98,;35.39,-5.36,;33.99,-4.67,;32.76,-5.6,;31.35,-5,;32.74,-7.14,;31.41,-7.9,;30.08,-7.12,;28.74,-7.88,;31.39,-9.44,;30.04,-10.2,;32.71,-10.23,)| Show InChI InChI=1S/C69H98N18O16S2/c1-38(2)27-46(60(95)82-50(30-42-21-23-44(89)24-22-42)66(101)87-26-14-20-52(87)63(98)83-51(36-104)67(102)103)79-54(91)35-86(6)55(92)34-76-59(94)47(28-40-15-9-7-10-16-40)81-61(96)49(31-43-32-73-37-77-43)78-53(90)33-75-64(99)56(39(3)88)84-65(100)57(69(4,5)105)85-62(97)48(29-41-17-11-8-12-18-41)80-58(93)45(70)19-13-25-74-68(71)72/h7-12,15-18,21-24,32,37-39,45-52,56-57,88-89,104-105H,13-14,19-20,25-31,33-36,70H2,1-6H3,(H,73,77)(H,75,99)(H,76,94)(H,78,90)(H,79,91)(H,80,93)(H,81,96)(H,82,95)(H,83,98)(H,84,100)(H,85,97)(H,102,103)(H4,71,72,74)/t39-,45+,46+,47+,48+,49+,50+,51+,52+,56+,57-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet 
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Inhibition of human IgG binding to soluble human FcRn by ELISA |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
IgG receptor FcRn large subunit p51
(Homo sapiens (Human)) | BDBM50270831
((2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S...)Show SMILES CC(C)C[C@H](NC(=O)CN(C)C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:80.82,95.100,28.36,50.60,42.44,4.4,74.78,wD:61.64,17.25,46.48,99.103,(29.75,3.77,;29.75,2.23,;31.09,1.45,;28.41,1.45,;28.41,-.09,;27.08,-.86,;25.75,-.09,;25.75,1.45,;24.42,-.86,;23.08,-.1,;23.09,1.44,;21.75,-.87,;21.75,-2.41,;20.42,-.1,;19.08,-.87,;17.75,-.1,;17.75,1.44,;16.42,-.87,;16.42,-2.41,;17.75,-3.18,;19.08,-2.41,;20.41,-3.18,;20.42,-4.72,;19.09,-5.49,;17.75,-4.73,;15.09,-.1,;13.76,-.88,;13.76,-2.42,;12.42,-.11,;12.42,1.44,;13.76,2.2,;15.17,1.58,;16.19,2.73,;15.42,4.06,;13.91,3.73,;11.08,-.86,;9.74,-.09,;9.74,1.45,;8.41,-.87,;7.08,-.08,;5.75,-.87,;5.75,-2.41,;4.42,-.1,;3.08,-.87,;1.75,-.1,;1.75,1.45,;.42,-.87,;-.91,-.1,;-2.24,-.88,;-2.24,-2.42,;-3.58,-.11,;-3.58,1.44,;-2.24,2.2,;-.9,1.43,;.43,2.2,;.43,3.75,;-.92,4.51,;-2.24,3.73,;-4.92,-.86,;-6.26,-.1,;-6.26,1.44,;-7.59,-.88,;-8.94,-.08,;-7.59,-2.41,;-6.26,-3.18,;-6.26,-4.72,;-4.92,-5.49,;-4.92,-7.03,;-6.27,-7.77,;-3.6,-7.79,;.42,-2.41,;1.97,-2.41,;-1.12,-2.4,;.42,-3.95,;4.42,1.45,;3.09,2.21,;5.75,2.21,;29.74,-.86,;29.74,-2.4,;31.08,-.09,;32.41,-.86,;33.74,-.09,;33.74,1.45,;32.42,2.22,;32.41,3.75,;33.75,4.53,;33.75,6.07,;35.08,3.77,;35.09,2.23,;32.41,-2.4,;31.08,-3.17,;33.74,-3.17,;35.32,-2.64,;36.34,-3.98,;35.39,-5.36,;33.99,-4.67,;32.76,-5.6,;31.35,-5,;32.74,-7.14,;31.41,-7.9,;30.08,-7.12,;28.74,-7.88,;31.39,-9.44,;30.04,-10.2,;32.71,-10.23,)| Show InChI InChI=1S/C69H98N18O16S2/c1-38(2)27-46(60(95)82-50(30-42-21-23-44(89)24-22-42)66(101)87-26-14-20-52(87)63(98)83-51(36-104)67(102)103)79-54(91)35-86(6)55(92)34-76-59(94)47(28-40-15-9-7-10-16-40)81-61(96)49(31-43-32-73-37-77-43)78-53(90)33-75-64(99)56(39(3)88)84-65(100)57(69(4,5)105)85-62(97)48(29-41-17-11-8-12-18-41)80-58(93)45(70)19-13-25-74-68(71)72/h7-12,15-18,21-24,32,37-39,45-52,56-57,88-89,104-105H,13-14,19-20,25-31,33-36,70H2,1-6H3,(H,73,77)(H,75,99)(H,76,94)(H,78,90)(H,79,91)(H,80,93)(H,81,96)(H,82,95)(H,83,98)(H,84,100)(H,85,97)(H,102,103)(H4,71,72,74)/t39-,45+,46+,47+,48+,49+,50+,51+,52+,56+,57-/m1/s1 | PDB
MMDB
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | 58 | n/a | n/a | n/a | 6.0 | n/a |
Syntonix Pharmaceuticals, Inc.
Curated by ChEMBL
| Assay Description
Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay |
Bioorg Med Chem 16: 6394-405 (2008)
Article DOI: 10.1016/j.bmc.2008.05.004
BindingDB Entry DOI: 10.7270/Q2QV3M9C |
More data for this
Ligand-Target Pair | |
Search and Browse
